30 August - 2 September 2024
European Society of Cardiology (ESC 2024)
Presentation schedule and materials
The congress symposium is no longer available
Friday, 30 August 2024
ORAL PRESENTATION
Atrial fibrillation and semaglutide effects in obesity-related HFpEF: prespecified patient level analysis of STEP-HFpEF and STEP-HFpEF DM trials
Subodh Verma1; Javed Butler2; Barry A. Borlaug3; Melanie J. Davies4; Dalane W. Kitzman5; Mark C. Petrie6; Sanjiv J. Shah7; Thomas J. Jensen8; Søren Rasmussen8; Cecilia Rönnbäck8; Bela Merkely9; Evan O’Keefe10; Mikhail N. Kosiborod10
MATERIALS AVAILABLE
ORAL PRESENTATION
Inflammation in obesity-related HFpEF: the STEP-HFpEF programme
Subodh Verma1; Mark C. Petrie2; Barry A. Borlaug3; Javed Butler4; Melanie J. Davies5; Dalane W. Kitzman6; Sanjiv J. Shah7; Cecilia Rönnbäck8; Steen Z. Abildstrøm8; Karoline Liisberg8; Mikhail N. Kosiborod9;
MATERIALS AVAILABLE
ORAL PRESENTATION
Effect of Semaglutide on Cardiac Structure and Function in Obesity-Related Heart Failure: The STEP-HFpEF Program Echocardiography Study
Scott Solomon1; Sanjiv J. Shah2; Barry A. Borlaug3; Javed Butler4,5; Melanie J. Davies6,7; Dalane W. Kitzman8; Mark C. Petrie9; Subodh Verma10; Steen Z. Abildstrøm11; Mette Nygaard Einfeldt11; Søren Rasmussen11; John W. Ostrominski1; Xiaowen Wang1; Mikhail N. Kosiborod12;
MATERIALS AVAILABLE
POSTER
Burden of systemic inflammation and associated health outcomes in adults with atherosclerotic cardiovascular disease managed in routine care: a longitudinal study of 84,399 participants from the SCREAM project
Faizan Mazhar1; Anne-Laure Faucon1; Edouard L Fu1,2; Karolina E Szummer3; Jimmi Mathisen4; Sofia Gerward4; Simon Bertram Reuter4; Nikolaus Marx5; Roxana Mehran6; Juan-Jesus Carrero1,7
MATERIALS AVAILABLE
ORAL PRESENTATION
Semaglutide in heart failure with mildly reduced and preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM randomised trials
Mikhail N Kosiborod1; John Deanfield2; Richard Pratley3; Søren Rasmussen4; Barry A Borlaug5; Javed Butler6; Melanie J Davies7; Scott Emerson8; Kenneth W Mahaffey9; Mark C. Petrie10; Sanjiv J Shah11; Subodh Verma12; Cecilia Rönnbäck4; Peter E. Weeke4; and Michael Lincoff13
MATERIALS AVAILABLE
ORAL PRESENTATION
Semaglutide and cardiovascular outcomes in females with overweight and obesity: An analysis of the SELECT trial
Subodh Verma1; Helen M. Colhoun2; Dror Dicker3,4; G. Kees Hovingh5,6; Steven E. Kahn7; Alexandra Kautzky-Willer8; Ildiko Lingvay9; Jorge Plutzky10; Søren Rasmussen5; Naveen Rathor5; Søren Tetens Hoff5; A. Michael Lincoff11; On behalf of the SELECT investigator group.
MATERIALS AVAILABLE
ORAL PRESENTATION
The effect of semaglutide on mortality and COVID-19-related deaths: An analysis from the SELECT trial
Benjamin M. Scirica1; Helen M. Colhoun2; John Deanfield3; Ole Kleist Jeppesen4; Peter E. Weeke4; Ildiko Lingvay5; Søren Østergaard Hardt-Lindberg4; Donna H. Ryan6; Ana Laura De Souza Almeida Matos4; A. Michael Lincoff7; On behalf of the SELECT investigator group.
MATERIALS AVAILABLE
Saturday, 31 August 2024
ORAL PRESENTATION
Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial
Helen M. Colhoun1; A. Michael Lincoff2; Martin Linder3; Søren Hardt-Lindberg3; G Kees Hovingh3,4; Steven E. Kahn5; Tugce Kalayci Oral3; Ildiko Lingvay6; Jorge Plutzky7; Donna H. Ryan8; Peter E. Weeke3; John Deanfield9; On behalf of the SELECT investigator group.
MATERIALS AVAILABLE
Sunday, 01 September 2024
POSTER
Awareness and perceptions of cardiologists towards systemic inflammation in atherosclerotic cardiovascular disease: A multi-national survey across 5 geographical regional sub-groups
Catapano A1; Komuro I2; Amir A Mohseni Zonoozi3; Prasad P3; Qian J4; Saraiva JFK5; Shete A6; Marx N7
MATERIALS AVAILABLE
ORAL PRESENTATION
Characterization of individuals with ASCVD, with and without CKD: results from a UK electronic health record database
Naveed Sattar1; Iram Faqir Muhammad2; Oscar Plunde2; Simon Bertram Reuter2; Zewei Shen3; Mads Jeppe Tarp-Johansen2; Lale Tokgözoğlu4; Kamlesh Khunti5
MATERIALS AVAILABLE
POSTER
Baseline patient reported outcomes in patients with peripheral artery disease and type 2 diabetes from STRIDE: a phase 3b, 52-week, randomised, double-blind, placebo-controlled trial
Subodh Verma1; Andrei-Mircea Catarig2; Yasemin Hansen2; Kim Houlind3; Chethana Kalmady Ramesh4; Bernhard Ludvik5; Joakim Nordanstig6; Neda Rasouli7; Harald Sourij8; Marc P. Bonaca9
Keywords